TRENDING TOPICS AND NEWS IN HCT AND CELLULAR THERAPY

A retrospective European Society for Blood and Marrow Transplantation (EBMT) registry study characterized the late effects of autologous hematopoietic stem cell transplantation (aHSCT) for severe...

Phase I/II clinical evidence suggests Evomela may be a viable conditioning agent for multiple myeloma (MM) patients preparing for autologous hematopoietic stem cell transplantation.

The endothelial interferon-γ-interferon regulatory factor 1 (IFNγ-IRF1) axis is implicated in the probability and severity of graft-versus-host disease (GVHD) following allogeneic hematopoietic...

Chimeric antigen receptor (CAR) T-cell therapy is inching closer to clinical success in solid tumors, according to researchers reporting on the performance of a CAR-like signal-switching...

Researchers report that following up brexucabtagene autoleucel (brexu-cel) treatment with tyrosine kinase inhibitor (TKI)-based maintenance therapy produces a survival benefit in adults with...

New evidence upholds bendamustine as a viable alternative to fludarabine in lymphodepleting (LD) chemotherapy ahead of chimeric antigen receptor (CAR) T-cell treatment.